Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0036690 (sepsis)
 59,461 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The most frequent cause of death in patients with severe burns is septicemia. Septicemia correlates with a decreased cellular immune defence in the patient. In the case of our patients with severe burns particularly a T-lymphocyte deficiency could be detected. This cellular immune deficiency induced by the thermic trauma was treated with thymostimulin (TP-1 Serono), an immunomodulating polypeptide preparation, which mainly influences T-lymphocytes. In this connection the efficacy of thymostimulin should be tested with respect to the incidence and course of the septicemia in patients with burns. 90 patients with burns of second and third degree and a risk of mortality of more than 20% according to Lynch have been included in the study. The efficacy of thymostimulin was proved by means of immunological tests and in the assessment of the posttraumatic clinical course. In the patient group treated with thymostimulin we were able to observe a significantly higher power of resistance to infections. This not only resulted in a decreased absolute mortality but also in a decreased mortality due to septicemia. The incidence of sepsis, however, could not be significantly influenced by the treatment. The E-rosette positive cells (= T-lymphocytes) as well as the T gamma-cells which are also responsible for the suppressor cell activity, could be normalized by the treatment, whereas the alterations of the TIa (turbidimetric immunoassay) positive cells were less evident.
 ...
PMID:Thymostimulin in the antiinfectious treatment in patients with burns. 349 38

A controlled study was carried out on 60 patients undergoing laparotomy to assess the role of a thymic factor (TP-1 Serono) in the prevention of postoperative infections. All patients entering the study were preoperatively shown to be at risk of sepsis on the basis of the response to skin multitest system for assay of delayed hypersensitivity (Multitest C.M.I. System). The patients were also postoperatively monitored with the same system. The lower incidence of infections in patients treated with the thymic factor with respect to untreated patients (p less than 0.05) and the postoperative response to skin tests have confirmed the efficacy of the thymic factor under study in the prevention of postoperative infections.
 ...
PMID:Use of a thymic factor in the prevention of postoperative infections. 406 75